Your SlideShare is downloading. ×
Sitagliptin 2015
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Sitagliptin 2015


Published on

This Presentation Give You A brief Information About DPP4 And New Recommendations .This Presentation Guide You How To Treat Patients With Safety. …

This Presentation Give You A brief Information About DPP4 And New Recommendations .This Presentation Guide You How To Treat Patients With Safety.
For Further Contact:03354999496

Published in: Health & Medicine
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. TREATMENT OF DIABETES - WHAT IS NEW ? Sitagen 50mg,100mg / Sitagen-M 50/500mg 1
  • 2. What is New in This Presentation 2 •Prevalence •Oral Anti Diabetics Agent •Management of Type 2 Diabetes •ADA Guidelines 2014 •Strategies for Antidiabetic Treatment •Master Decision Path For Type 2 Diabetes Glycemic Control •Incretins – What are they? •What Is DPP-4? •Newer Therapies •Sitagliptin MOA •Clinical Evidence •Summary of Sitagliptin
  • 3. Prevalence 3 •In Pakistan 12.9 Million people with diabetes( 10% of total population) •Diagnosed: 9.4 million •Undiagnosed: 3.5milliion •Pre diabetes: 38 million people 10% 90% Type 1 diabetes Type 2 diabetes
  • 4. 4 Choice of agents in current use a) Sulfonylureas b) Insulin c) Thiazolidindiones (TZDs) d) Biguanides e) α- Glucosidase inhibitors f) Meglitinides
  • 5. All Current Treatments for Type 2 Diabetes Have Limitations Sulfonyl- ureas Insulin Meglitinides Metformin Acarbose Thiazolidi- nediones Hypoglycemia √ √ √ Weigh gain √ √ √ √ GI side effects √ √ Lactic acidosis √ Homocystein √ Edema √ Inability to achieve normoglycemia √ √ √ Fluid Retention √ Tripathi.2005 5th edition Nature Reviews.2007;6:109-110 Pharmacology & Therapeutics.2010:125;328–3615
  • 6. No Single Class of Oral Antihyperglycemic Monotherapy Targets All Key Pathophysiologies Alpha- Glucosidase Inhibitors1,2 Meglitinide s3 SUs4,5 TZDs6,7 Metformi n8 DPP-4 Inhibitors Insulin deficiency Insulin resistance Excess hepatic glucose output MajorPathophysiology's 1. Glyset [package insert]. New York, NY: Pfizer Inc; 2004. 2. Precose [package insert]. West Haven, Conn: Bayer; 2004. 3. Prandin [package insert]. Princeton, NJ: Novo Nordisk; 2006. 4. Diabeta [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2007. 5. Glucotrol [package insert]. New York, NY: Pfizer Inc; 2006. 6. Actos [package insert]. Lincolnshire, Ill: Takeda Pharmaceuticals; 2004. 7. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005. 8. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2004.         Intestinal glucose absorption 
  • 7. Basic Steps in the Management of Type 2 Diabetes + + +
  • 8. Strategies for Antidiabetic Treatment Oral Triple Combination Therapy plus Basal Insulin or plus GLP-1-Mimeticum Oral Monotherapy Oral Dual Combination Therapy Oral Triple Combination Therapy NPG, Glargine, Levemir Metformin + Sulfonylureas+DPP-4- Inhib. Metformin + Sulfonylureas + TZDs Metformin DPP-4 Inhibitors Glinides TZDs Sulfonylureas -Glucosidase-Inhibitors Metformin + DPP-4-Inhibitors Sulfonylureas + DPP-4-Inhibitors Metformin + Sulfonylureas Sulfonylureas + TZDs Metformin + TZDs Exenatide, Liraglutide
  • 9. Master Decision Path Type 2 Diabetes Glycemic Control Medical Nutrition Therapy & Activity Plan start monotherapy Oral combination treatment 2 drugs If target not reached after maximum dose for 4 - 8 weeks - - start oral agent Insulin Therapy Oral Agent(s) + Insulin Oral Combination Rx 3 drugs If target not reached after maximum doses for 4 - 8 weeks -- start insulin FPG < 200 Casual < 250 FPG 200-300 Casual 250-350 FPG > 350 Casual > 400 At Diagnosis (mg/dl) Targets for Glycemic Control HbA1c <7% FPG > 300-350 Casual > 350-400 with severe symptom KK/ESSENTIAL DRUG/3.4.11/tAUNGGHU
  • 10. 11 Incretins – What are they? Hormones produced by the gastrointestinal tract in response to incoming nutrients, and have important actions that contribute to glucose homeostasis. Two hormones: Gastric inhibitory polypeptide (GIP) Glucagon-like peptide-1 (GLP-1). INCRETIN= INtestinal+seCRETion of INsulin
  • 11. 12 GLP-1: Effects in Humans • Stimulate glucose dependant insulin secretion • Suppresses glucagon secretion • Slows gastric emptying • Reduces food intake • Improves insulin sensitivity Clinical Therapeutics.2006;28(1):55 Pharmacology & Therapeutics.2010:125;328–361
  • 12. What Is DPP-4? • A serine protease widely distributed throughout the body • Cleaves N-terminal amino acids of a number of biologically active peptides, including the incretins GLP-1 and gastric inhibitory peptide (GIP), resulting in inactivation • Its effects on GLP-1 and GIP have been shown to affect Incretins activity • Inactivates GLP-1 >50% in ~1 to 2 minutes Ahrën B. Curr Enzyme Inhib. 2005;1:65-73.
  • 13. DPP-4
  • 14. Inhibition of DPP-4 Increases ActiveGLP-1
  • 15. GLP-1 and GIP Are Degraded by the DPP-4 Enzyme Meal Intestinal GIP and GLP-1 release GIP and GLP-1 Actions DPP-4 Enzyme GIP-(1–42) GLP-1(7–36) Intact GIP-(3–42) GLP-1(9–36) Metabolites Rapid Inactivation Half-life* GLP-1 ~ 2 minutes GIP ~ 5 minutes Deacon CF et al. Diabetes. 1995;44:1126–1131. *Meier JJ et al. Diabetes. 2004;53:654–662.
  • 16. Food intake Stomach GI tract Intestine Increases and prolongs GLP-1 effect on alpha-cells: Alpha-cells Pancreas Insulin release Net effect: Blood glucose Beta-cells Increases and prolongs GLP-1 and GIP effects on beta-cells: DPP-4 inhibitor Glucagon secretion Incretins DPP-4 DPP-4 Inhibitors Enhance Incretin and Insulin Secretion Adapted from: Barnett A. Int J Clin Pract 2006;60:1454-70 Drucker DJ, Nauck MA. Nature 2006;368:1696-705 Idris I, Donnelly R. Diabetes Obes Metab 2007;9:153-65
  • 17. 18 Newer Therapies  GLP-1 analogs: Exenatide  Dipeptidyl Peptidase-4 (DPP 4) inhibitors: Sitagliptin, Saxagliptin, Vildagliptin Pharmacology & Therapeutics.2010:125;328–361
  • 18. 19 DPP4 inhibitors such as Sitagliptin Inhibit the degradation of incretins and thus Prolong the half life of Endogenous Incretins Action of Sitagliptin is Glucose-Dependent And Hence Hypoglycemia is Less Common
  • 19. Drug Review.2008;10(2):97-98 • Reduces hemoglobin A1c (HbA1c), fasting and postprandial glucose by glucose dependant stimulation of insulin secretion and inhibition of glucagon secretion. • Sitagliptin is selective inhibitor of the enzyme DPP-4. • Delays gastric emptying and reduce appetite. 20 SITAGLIPTIN 20 Mechanism of action (MOA)
  • 20. 21
  • 21. Pharmacokinetics  Bioavailability of Sitagliptin is approximately 87% .  Half life is between 8-14 hours.  It is 38% bound to plasma proteins.  Elimination is mainly through urine. Drug Review.2008;10(2):97-9822
  • 22. 23 a) reducing both fasting and postprandial glucose concentration, b) clinically meaningful reductions in glycosylated hemoglobin (HbA1c) levels in type 2 diabetic patients. • Monotherapy with Sitagliptin 100 mg daily decreases mean HbA1c by 0.6-0.98%. CLINICAL EVIDENCE Drug Review.2008;10(2):97-98 Consultant.2009:S5-11 Pharmacology & Therapeutics.2010;25:328-361 • In very well controlled randomized clinical trials Sitagliptin (100 mg) treatment significantly improved glycemic control by • Improved Homeostasis model assessment of β cell and Proinsulin-to-insulin ratio.
  • 23. 24 • Sitagliptin (100 mg) monotherapy for 18 weeks significantly improved glycemic control by reducing HbA1c, fasting and postprandial glucose in Indian type 2 diabetic (T2D) patients . Efficacy & Safety of Sitagliptin in Indian T2D patients • Sitagliptin was well tolerated and no hypoglycemia reported. Diabetes Research and Clinical Practice.2009;83:106-116
  • 24. 25 Sitagliptin and Blood Pressure J Clin Pharmacol. 2008 May;48(5):592 Tohoku.J.Exp.Med.2011;223:133-135 • Sitagliptin treatment significantly reduced blood pressure and was well tolerated in type 2 diabetic and non-diabetic hypertensive patients.
  • 25. 26 Sitagliptin and Inflammatory Markers • Sitagliptin (100 mg) treatment for 3 months decreased inflammatory markers C-reactive protein (CRP), Interleukin-6 (IL-6), Myeloperoxidase (MPO), Monocyte chemotactic protein-1 (MCP-1) in type 2 diabetic patients with atherosclerosis. • Changes in markers levels correlated with the improvement of glycemic control as shown by Hb A1c. Journal of Clinical Lipidology.2008;2(5S):S137-138
  • 26. 27 Sitagliptin Vs Voglibose Diabetes Obese Metab.2010;12(7):613-22 • In comparative, randomized clinical trial, once daily Sitagliptin monotherapy showed greater efficacy and better tolerability than thrice daily Voglibose (alpha- glucosidase inhibitor) over 12 week in type 2 diabetes patients.  Significantly reduced HbA1c  Significant lowered side effects  Significantly reduced fasting and postprandial plasma glucose
  • 27. 28
  • 28. 29
  • 29. Side Effects • In clinical trials, Sitagliptin demonstrated an overall incidence of side effects comparable to placebo. • The incidence of Hypoglycemia with Sitagliptin monotherapy was not Significantly different than placebo. • Upper respiratory tract infection, stuffy or running nose, sore throat, headache and diarrhea was reported with Sitagliptin are rare. Drug Review.2008;10(2):97-9830 • No significant change in body weight was reported.
  • 30. 31 • The recommended dose of Sitagliptin is 100 mg once daily. It may be taken with or without food. •Maximum Dose 200mg/day •If administered with sulfonylurea: a reduced dose of sulfonylurea may be required. Recommended Dosage
  • 31. Drug Interaction • Sitagliptin plasma concentration may be increased modest (approximately 68%) with Cyclosporine which is not expected to be clinically important. • Digoxin plasma levels may be increased slightly (approximately18%), no dosage adjustment is recommended. • Care should be taken with drugs that can potentially lower blood sugar, such as: Probencid, NSAIDs, Aspirin, Sulfa drugs, MAO inhibitors or Beta blockers. Drug Review.2008;10(2):97-9832
  • 32. Contraindications • Sitagliptin is a pregnancy category B drug. • Sitagliptin is contraindicated in diabetic ketoacidosis.  In severe renal function impairment (Ccr less than 30 mL/min) dose should be reduced to 25 mg once daily.  In moderate renal function impairment (Ccr 30 to less than 50mL/min) dose should be reduced to 50mg once daily. • Dosage adjustments are needed in patients with moderate or severe renal function impairment. 33Drug Review.2008;10(2):97-98
  • 33. 34 • In October 2006, the U.S. Food and Drug Administration (FDA) approved Sitagliptin as monotherapy and as add-on therapy to either of two other types of oral diabetes medications. • In April, 2007 FDA approved the combination product of Sitagliptin and Metformin for type 2 diabetes. • In March, 2007 it was approved in European Union. • Sitagliptin is currently approved in 70 Countries. Regulatory Affairs
  • 34. 35 Summary of Sitagliptin  No clinically meaningful hypoglycemia  Weight neutral  DPP-4 Inhibitor  Good tolerability  Improves Blood pressure  Stimulate insulin secretion  Slows gastric emptying  Reduces food intake  Inhibit glucagon secretion  Reduces HbA1c  Improves inflammatory markers
  • 35. 36